Khindivi is a drug owned by Eton Pharmaceuticals Inc. It is protected by 2 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 23, 2043. Details of Khindivi's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12133914 | NA |
Feb, 2043
(17 years from now) | Active |
| US11904046 | NA |
Feb, 2043
(17 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Khindivi is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Khindivi's family patents as well as insights into ongoing legal events on those patents.
Khindivi's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Khindivi's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 23, 2043 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Khindivi Generic API suppliers:
Hydrocortisone is the generic name for the brand Khindivi. 70 different companies have already filed for the generic of Khindivi, with Taro having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Khindivi's generic
Alternative Brands for Khindivi
There are several other brand drugs using the same active ingredient (Hydrocortisone) as Khindivi. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Bausch |
| ||
| Eton |
| ||
| Precision Dermat |
| ||
| Sandoz |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Hydrocortisone, Khindivi's active ingredient. Check the complete list of approved generic manufacturers for Khindivi
About Khindivi
Khindivi is a drug owned by Eton Pharmaceuticals Inc. Khindivi uses Hydrocortisone as an active ingredient. Khindivi was launched by Eton in 2025.
Approval Date:
Khindivi was approved by FDA for market use on 28 May, 2025.
Active Ingredient:
Khindivi uses Hydrocortisone as the active ingredient. Check out other Drugs and Companies using Hydrocortisone ingredient
Dosage:
Khindivi is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1MG/ML | SOLUTION | Prescription | ORAL |